WA
FATE icon

Wilshire Advisors’s Fate Therapeutics FATE Stock Holding History

Wilshire Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,486,822
Closed -$10.7M – 8
2025
Q3 		$10.7M Buy
+8,486,822
New +$9.15M 27.71% 2
2025
Q2 		– Sell
-4,083
Closed -$13.2K – 10
2025
Q1 		$13.2K Hold
4,083
– – 0.04% 13
2024
Q4 		$7K Hold
4,083
– – ﹤0.01% 11
2024
Q3 		$15K Hold
4,083
– – 0.01% 11
2024
Q2 		$13.4K Hold
4,083
– – 0.01% 11
2024
Q1 		$30K Hold
4,083
– – 0.01% 11
2023
Q4 		$15.3K Buy
+4,083
New +$9.64K 0.01% 11
2022
Q3 		– Sell
-4,083
Closed -$101K – 12
2022
Q2 		$101K Hold
4,083
– – 0.05% 10
2022
Q1 		$158K Hold
4,083
– – 0.07% 10
2021
Q4 		$239K Hold
4,083
– – 0.09% 13
2021
Q3 		$242K Buy
+4,083
New +$320K 0.64% 9

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Wilshire Advisors's FATE Position: Q4 2025 in Review

Wilshire Advisors sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 8,486,822 shares — an estimated $10.7M sold.

Wilshire Advisors first reported a position in FATE in Q3 2021 and held it in 11 quarters. The position peaked at $10.7M in Q3 2025. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Wilshire Advisors reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wilshire Advisors sold 8,486,822 Fate Therapeutics shares in Q4 2025, an estimated $10.7M.
  • Wilshire Advisors first reported a position in Fate Therapeutics in Q3 2021 and held it in 11 quarters.
  • Wilshire Advisors's Fate Therapeutics position peaked at $10.7M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Wilshire Advisors's 13F filing for Q4 2025, filed 27 May 2026.